Granules India‘s Gagillapur Plant gets an all-clear certificate from Portuguese Regulator INFARMED post re-inspection done from January 31 to Feb 2.
Granules India gets US FDA approval for orange-coloured 200 mg version of ibuprofen. Speaking to CNBC-TV18, C Krishna Prasad said that the market for orange-coloured tablet is around USD 49 million.
In an interview with CNBC-TV18, C Krishna Prasad, MD of Granules India said that four domestic plants were inspected by USFDA and one plant is due for inspection soon.
C Krishna Prasad, MD, Granules India says margins in contract research and manufacturing services (CRAMS) business is relatively high and expects 30-35 percent of capacity utilization in the same.
C Krishna Prasad, Managing Director (MD) of Granules India said with only three to four main competitors in the US market, the company‘s topline and bottomline will benefit from the drug.
C Krishna Prasad, MD, Granules India says the company has secured businesses from Wal-Mart and CVS and incremental benefits will come going forward.
Revenue growth for the global pharmaceutical company stands at 15 percent for FY15 and 25 percent for FY16. Going ahead, the company awaits FDA approval for their new plant, C Krishna Prasad adds.
Speaking to CNBC-TV18 on the acquisition of the Rs 100 crore company, C Krishna Prasad, managing director, Granules India, says the deal has been funded by a mix of accruals and debt.
"We have expanded significantly over the last two years, our assets are yielding right now a lot of the profit is because of growth in revenue," Granules India executive director Harsha Chigurupati said elaborating reasons for strong growth.